ELOVL2

ELOVL2 — The DHA Synthesis Bottleneck

Your body can make [DHA | docosahexaenoic acid — the primary omega-3 fat in brain tissue,
the retina, and cell membranes throughout the nervous system] from shorter omega-3 fats,
but the last elongation step is rate-limiting. ELOVL2 (elongation of very long chain fatty
acids 2) is the enzyme responsible for converting DPA into the final DHA product.
Variants at the ELOVL2 locus | rs3734398 is a 3′ UTR variant at chromosome 6p24.2 that
influences ELOVL2 expression and enzyme efficiency
substantially change how much DHA reaches the bloodstream — regardless of how much fish you eat.

ELOVL2 has a second claim to fame: its promoter methylation is the strongest known epigenetic
clock signal in the human genome. DNA methylation at this locus | ELOVL2 methylation
accumulates linearly from birth to old age, explaining 70% of the variance in epigenetic
age across multiple tissues increases with
every year of life, a finding replicated in hundreds of age-estimation studies. The rs3734398
variant sits at the junction of two of the most important health-related biological processes:
DHA metabolism and epigenetic aging.

The Mechanism

The omega-3 synthesis pathway runs: ALA → EPA → DPA → DHA. ELOVL2 catalyzes the
penultimate elongation step (DPA → 24:5n-3), and the downstream desaturase then produces
DHA via 24:6n-3. The rs3734398 C allele alters expression of the ELOVL2 3′ UTR, modifying
enzyme activity in a way that partially impairs the DPA-to-DHA conversion | carriers
accumulate more DPA substrate and produce less DHA product, explaining the simultaneous
elevation of EPA+DPA and reduction of DHA observed in GWAS. This is a
functional bottleneck: the upstream elongation steps are not affected, so EPA and DPA build
up while DHA output falls.

Importantly, the C allele also appears to be associated with higher ELOVL2 mRNA expression
| Dai et al. (2019) found CC genotype was associated with significantly increased ELOVL2
mRNA levels in melanoma tissue, suggesting the
variant may produce a qualitatively different enzyme or alter splicing rather than simply
reducing transcription. The precise molecular mechanism at the 3′ UTR remains under study.

The Evidence

The landmark CHARGE Consortium GWAS meta-analysis | Lemaitre RN et al. Genetic loci
associated with plasma phospholipid n-3 fatty acids. PLoS Genet, 2011
across 8,866 individuals of European ancestry established the ELOVL2 locus as one of only
three genome-wide significant loci for plasma phospholipid omega-3 fatty acids. The C allele
was associated with higher EPA (p=2×10⁻¹²) and DPA (p=1×10⁻⁴³) but lower DHA (p=1×10⁻¹⁵),
consistent across all ancestry groups with sufficient C-allele polymorphism.

The MARINA randomized trial by Alsaleh et al. | Alsaleh A et al. ELOVL2 gene polymorphisms
are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions
after fish oil supplement. Genes Nutr, 2014
(n=310, six months, up to 1.8 g/day EPA+DHA) showed that C-allele carriers had significantly
lower plasma DHA at baseline (p=0.021) but responded more robustly to supplementation: at
1.8 g/day, C-allele carriers gained 25.7% more EPA (p=0.003) and 8.7% more DHA (p=0.016)
relative to TT homozygotes. The dose-response was significant only at the highest dose tested.

In a separate melanoma survival cohort, the C allele was associated with lower
all-cause melanoma mortality | Dai W et al. Genetic variants in ELOVL2 and HSD17B12
predict melanoma-specific survival. Int J Cancer, 2019
(HR=0.66, 95% CI 0.51–0.84), an association the authors attributed to ELOVL2-mediated effects
on PUFA composition and cellular membrane integrity. The CC genotype was associated with
increased ELOVL2 mRNA expression in tumor tissue, suggesting complex genotype-expression
relationships that extend beyond simple DHA reduction.

Practical Actions

For C-allele carriers (CT or CC), the core implication is that dietary conversion of EPA
to DHA is less efficient than average. Plant-based omega-3 sources (ALA from flax, chia,
walnuts) are even less useful than usual, since they must traverse the entire conversion
pathway including this bottleneck. Preformed EPA and DHA from marine or algae-based sources
bypass the impaired elongation step and directly raise plasma DHA. At the 1.8 g/day dose
used in MARINA, C-allele carriers showed a greater absolute response than TT homozygotes,
so the supplement recommendation has direct evidence, not just theoretical support.

TT homozygotes have the most efficient DHA synthesis from DPA and can maintain higher plasma
DHA levels on habitual diet. They still benefit from dietary EPA/DHA sources, but the urgency
for supplementation is lower.

Interactions

rs3734398 sits in the same biological pathway as the FADS1/FADS2 desaturase variants
(rs174547 and related), which operate earlier in the omega-3 synthesis chain (ALA→EPA,
EPA→DPA). A person carrying both FADS1/FADS2 risk variants AND the ELOVL2 C allele faces
impairment at multiple sequential steps of DHA synthesis, making the need for preformed
marine EPA/DHA substantially greater than either variant alone. rs2236212 is in near-complete
linkage disequilibrium with rs3734398 (r²=0.966) and is the same functional signal; users
who have data on one effectively have data on both.